• Home
  • News
  • Stephenson Harwood advises Oxford Biomedica on further Covid-19 vaccine deal

04 Sep 2020

Stephenson Harwood advises Oxford Biomedica on further Covid-19 vaccine deal

Linkedin

Law firm Stephenson Harwood LLP has advised gene and cell therapy company Oxford Biomedica on a second supply agreement with AstraZeneca, to expand the manufacturing support of Covid-19 vaccine, AZD1222. This agreement builds on the supply agreement between the companies, which was announced on 28 May.

The 18 month agreement with AstraZeneca, part of a three year master supply and development agreement, is for the large-scale commercial manufacture of the adenovirus vector-based Covid-19 vaccine, AZD1222. Under the terms of the agreement, AstraZeneca will pay Oxford Biomedica £15 million as a capacity reservation fee. Subject to satisfactory manufacturing capacity and the continuation of the vaccine programme, Oxford Biomedica will receive additional revenue in excess of £35 million, plus certain material costs.

The Stephenson Harwood team was led by partner Dan Holland, with support from senior associate Chloe Haywood. Further assistance was provided by partners Maryanna Sharrock and Alexandra Pygall, and senior associate Jodie Lilir.

Linkedin

KEY CONTACT

Dan Holland

Dan Holland
Partner

T:  +44 20 7809 2108 M:  +44 7841 923 656 Email Dan | Vcard Office:  London

Alexandra Pygall

Alexandra Pygall
Partner

T:  +44 20 7809 2137 M:  +44 7881 314 566 Email Alexandra | Vcard Office:  London

Maryanna Sharrock

Maryanna Sharrock
Partner

T:  +44 20 7809 2191 M:  Email Maryanna | Vcard Office:  London

Jodie Lilir

Jodie Lilir
Senior associate (Registered in New South Wales)

T:  +44 20 7809 2715 M:  +44 7584 216 661 Email Jodie | Vcard Office:  London

MEDIA CONTACT

Andrew Rieley
Head of communications and PR
T: +44 20 7809 2886
Email Andrew